Diagnosis-related groups in oncology and oncohematology
https://doi.org/10.21682/2311-1267-2025-12-4-102-109
Abstract
The article presents issues related to the payment for medical care in oncology/oncohematology profile in 24-hour and day inpatient hospital hospital settings. The main changes that have occurred in recent years in the formation of profile clinical and statistical groups are presented, and emphasis is placed on the correctness of determining the total cost of a case when paying for it according to the clinical and statistical groups and the cost-effectiveness of hospitalization of profile patients in a 24-hour hospital.
About the Authors
A. A. IvanovaRussian Federation
Dr. of Sci. (Med.), Methodist of the Organizational and Methodological Department with the Cancer Register and the Medical Archive of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov; Project Manager; Professor of the Department of Public Health care named after Academician Y.P. Lisitsyn and of the Department of Oncology, Hematology and Radiation Therapy
23 Kashirskoe Shosse, Moscow, 115522
1 Ostrovityanova St., Moscow, 117997
11 Dmitry Ulyanov St., Moscow, 117292
A. A. Malakhova
Russian Federation
Cand. of Sci. (Med.), Pediatric Oncologist, Head of the Organizational and Methodological Department with the Cancer Register and the Medical Archive of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov
23 Kashirskoe Shosse, Moscow, 115522
T. V. Gorbunova
Russian Federation
Cand. of Sci. (Med.), Deputy Chief Physician for Medical Affairs and Senior Researcher of the Oncology Department No. 3 (Chemotherapy of Head and Neck Tumors) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov
23 Kashirskoe Shosse, Moscow, 115522
V. V. Omelyanovsky
Russian Federation
Dr. of Sci. (Med.), Professor, General Director
Bldg. 2, 6/20 Pokrovsky Boulevard, Moscow, 109028
K. I. Kirgizov
Russian Federation
Cand. of Sci. (Med.), Deputy Director for Scientific Work of Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov
23 Kashirskoe Shosse, Moscow, 115522
S. R. Varfolomeeva
Russian Federation
Dr. of Sci. (Med.), Professor, Director of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durno; Professor at the Department of Pediatric Oncology named after Academician L.A. Durnov
23 Kashirskoe Shosse, Moscow, 115522
Bldg. 1, 2/1 Barrikadnaya St., Moscow, 125993
References
1. Rumyantseva E.I., Zheleznyakova I.A., Plakhotnik O.S., Nikitin F.S., Vakhrusheva T.S., Avyaeva T.S., Zuev A.V., Volkova O.A., Agafonova Yu.A., Fedyaev D.V., Avksentieva M.V., Omelyanovsky V.V. Major changes in the payment model for medical care by clinical and statistical groups in the Russian Federation in 2024. Meditsinskie tekhnologii. Otsenka i vybor = Medical Technologies. Assessment and Choice. 2024;46(2):10–21. (In Russ.)].
2. Plakhotnik O.S., Trifonova G.V., Zheleznyakova I.A., Mazurov A.M., Volkova O.A., Avyaeva T.S., Zuev A.V., Zueva Yu.S., Agafonova Yu.A., Sidorova E.A., Lazareva M.L., Fedyaev D.V., Avxentyeva M.V., Omelyanovskiy V.V. Main changes in payment model for diagnosis-related groups in the Russian Federation in 2023. Meditsinskie tekhnologii. Otsenka i vybor = Medical Technologies. Assessment and Choice. 2023;45(2):8–22. (In Russ.)].
3. Resolution of the Government of the Russian Federation of December 27, 2024, No. 1940 “On the Program of State Guarantees of Free Medical Assistance to Citizens for 2025 and for the Planning Period of 2026 and 2027”. (In Russ.)].
4. Methodological recommendations on the methods of payment for medical care at the expense of compulsory medical insurance (approved by the Ministry of Health of the Russian Federation and the Federal Compulsory Medical Insurance Fund on January 28, 2025. No. 31-2/115/00-10-26-2-06/965) (In Russ.)].
5. Zheleznyakova I.A. Regulatory legal regulation of the organization and fi nancial provision of supportive therapy for oncological diseases and directions for its optimization. Nacional'noe zdravookhranenie = National Health Care (Russia). 2024;5(4):38–50. (In Russ.)].
6. Derkach E.V., Pyadushkina E.A., Avxentyeva M.V., Boyarskaya T.V., Yagnenkova E.E., Mokrova A.S., Maryanyan M.M. The use of various genetically engineered biological drugs and selective immunosuppressants within the current providerpayment model of russian diagnosis-related groups Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Farmakoekonomika Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(3):225–39. (In Russ.)].
Review
For citations:
Ivanova A.A., Malakhova A.A., Gorbunova T.V., Omelyanovsky V.V., Kirgizov K.I., Varfolomeeva S.R. Diagnosis-related groups in oncology and oncohematology. Russian Journal of Pediatric Hematology and Oncology. 2025;12(4):102-109. (In Russ.) https://doi.org/10.21682/2311-1267-2025-12-4-102-109
JATS XML


























